This cohort study assesses the association between glucagon-like peptide-1 receptor agonist use and the development or progression of age-related macular degeneration compared with other weight loss d...

Tocilizumab effectively reduced relapse rates and demonstrated glucocorticoid-sparing effects in patients with refractory PMR in the real world, with no significant safety issues. These results furthe...

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.Those who used GLP-1 receptor agonists exhibited signif...

LICATS is a new form of toxicity in patients with autoimmune disease receiving CD19-targeting CAR T-cell therapy, most likely based on the cleansing of immune cells from the affected organs. It is sel...

This randomized clinical trial assesses the effect of metformin on knee pain among patients with symptomatic knee osteoarthritis and overweight or obesity.

Quick Take Video Summary from The New England Journal of Medicine — Tolebrutinib versus Teriflunomide in Multiple Sclerosis

Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Table 1 summarizes t...

In this study of RA patients, history of VTE and recent hospitalisation were identified as strong risk factors of VTE. Moreover, it emphasises the importance of evaluating cardiovascular risk…

AbstractBackground and Aims. Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular ev

Nature Reviews Rheumatology, Published online: 06 May 2025; doi:10.1038/s41584-025-01252-7Systemic vasculitis, including monogenic forms, is associated with an increased risk of arterial and venous thromboembolic events (AVTEs). This Review highlights the latest advances in the understanding of the pathogenesis, clinical features and management of AVTEs in systemic and monogenic vasculitis.

Our finding suggest that first-generation GLP1-RA treatment does not increase ORC risk in patients receiving GLP1-RA treatment for diabetes and weight loss. Moreover, this may point at additional path...

A compelling new study adds to the body of data supporting some protection provided by the vaccine

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several...

AbstractObjective. Arthritis is associated with a worse prognosis in established SSc. However, knowledge about its relevance in very early SSc (veSSc) is s

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary...

Research reveals how a specific mutation in a protein called TRAF1 can shut down an overactive immune response, dramatically reducing inflammation in mice. This discovery could pave the way for a new…

Objectives To determine the features of rheumatoid pulmonary nodules and the factors associated with nodule progression in patients with rheumatoid arthritis. Methods Between January 2010 and…

We provide the first evidence that CD19-targeting CAR T-cell therapy might intercept with the progression of fibrotic organ manifestations in patients with systemic sclerosis.

AbstractObjectives. The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM).

New pathogenesis-based therapeutics and evidence-based consensus treatment recommendations, often with predefined treatment goals, have remarkably improved outcomes across many chronic diseases. Howev...